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Behçet’s disease (BD) is a systemic inflammatory disorder charac- 
terized by a protean clinical spectrum and an enigmatic patho- 
genesis. After being classified as an autoimmune disorder, 
spondyloarthritis and vasculitis, today BD is considered at 
the crossroad between autoimmune and auto-inflammatory 
syndromes. Many pathogenetic, clinical and therapeutic clues 
support this recent interpretation, enabling novel treatment 
choices such as interleukin (IL)-1 inhibition. Thus, in the last 
decade the IL-1 receptor antagonist anakinra and the anti-
IL-1β monoclonal antibody canakinumab were increasingly 
administered in BD patients resistant to standard therapies, 
leading to interesting results and intriguing new pathogenetic 
implications. However, further studies are essential to both 
establish how the innate and acquired immune systems 
interact in BD patients and identify the best way of admin- 
istering anti-IL-1 agents with regard to dosage, interval of 
administration, and organ response.
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B ehçet’s disease (BD) is a systemic inflammatory disorder affecting a wide range of organs and tissues. In particular, 
skin lesions, arthritis, venous thrombosis, arterial aneurysms, 
intestinal ulcers, pulmonary lesions, and central nervous sys-
tem manifestations represent potential clinical signs of BD, in 
addition to the originally described triad of recurrent oral aph-
thosis, genital ulcers and uveitis [1]. Although BD is generally 
not a life-threatening condition, mortality can be associated 
with vascular-thrombotic and neurological manifestations [2].
To date, the pathogenesis of BD is mostly unknown. 
However, after being repeatedly classified, BD is now regarded 
at the crossroad between autoimmune and auto-inflammatory 
syndromes. The current definition of auto-inflammatory dis-
eases identifies a wide number of conditions manifesting with 
seemingly unprovoked episodes of recurrent inflammation [3]. 
This notion was first proposed on the basis of clinical observa-
tions identifying BD as an inflammatory disorder characterized 
by a relapsing-remitting disease course with a lack of autoanti-
bodies or autoreactive antigen-specific T cells, as in monogenic 
auto-inflammatory syndromes (MAIS) [4,5]. Many efforts have 
been made in the last decade to discover pathogenetic connec-
tions and overlapping pathways between BD and MAIS, thus 
considerably expanding the treatment options for BD. With 
regard to children, while management recommendations are 
available for other vasculitic syndromes, such as Kawasaki 
disease [6], neither therapeutic paradigms nor evidence-
based guidelines are available for BD occurring in childhood. 
However, on the basis of a new pathogenetic interpretation of 
BD, further treatment tools beyond anti-tumor necrosis factor 
(TNF) therapies have recently been suggested [7]. In particular, 
interleukin (IL)-1β inhibition, representing the cornerstone of 
therapy in adult and pediatric patients diagnosed with different 
MAIS, was recently investigated as a potential option for BD 
resistant to standard treatment [3].
This review will present current evidence on the role of 
innate immunity in BD, including pathogenetic and clinical 
findings along with the newest findings on IL-1 inhibition as 
an effective treatment approach for BD patients.
PAThOGEnETIC EVIDEnCE
Although BD pathogenesis is still not completely known, neu-
trophils are deemed to be central in BD, and increased produc-
tion of IL-8, TNFα and IL-1 from lymphomononuclear and/
or endothelial cells contribute to neutrophil activation in these 
patients. More specifically, neutrophils seem to be activated by 
a particular subset of IL-8-producing T cells that secrete TNFα, 
which in turn induces the production of other pro-inflamma-
tory cytokines such as IL-1 [8]. As a result, the role of IL-1 as 
a pivotal cytokine in BD pathogenesis is considered a crucial 
clue for classifying BD among polygenic auto-inflammatory 
disorders. In particular, IL-1 was found to be significantly 
higher in patients with both active and inactive BD compared 
to healthy controls. Notably, lipopolysaccharide-induced pro-
duction of IL-1 by monocytes was even higher in BD patients 
compared to patients with familial Mediterranean fever (FMF), 
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the most important among MAIS [9]. Furthermore, IL-33, a 
recently identified member of the IL-1 family involved in innate 
immunity, was increased in the sera of BD patients along with 
its soluble ligand sST2. Moreover, serum sST2 level significantly 
correlated with BD activity, evaluated with the BD currently 
active form (BDCAF), Iranian BD dynamic activity measure 
(IBDDAM), erythrocyte sedimentation rate and C-reactive 
protein. In addition, both IL-33 and sST2 were highly expressed 
in the epidermis and dermis of patients with BD compared to 
healthy controls [10].
Noteworthy, single nuclear polymorphisms of IL-1 gene were 
also found to be significantly more represented in patients with 
BD in different ethnic groups. In particular, susceptibility to BD 
was increased in individuals carrying the IL-1β+3953 T allele 
and TT genotype, the IL-1α -889C and IL-1β +5887T haplo-
types as well as the IL-1β-511 and IL-1β + 3962C alleles [11]. 
In order to identify any relationship with innate immunity 
in BD pathogenesis, the NACHT, LRR and PYD domains con-
taining protein 3 (NLRP3) inflammasome was recently investi-
gated in BD patients. NLRP3 inflammasome is an intracellular 
multiprotein complex leading to the secretion of inflammatory 
cytokines via caspase-1 activation. In particular, the NLRP3 
inflammasome leads to the active secretion of IL-1β and is 
closely involved in the pathogenesis of MAIS, in particular FMF 
and cryopyrin-associated periodic syndrome (CAPS) [12]. 
Regarding BD, mRNA and protein levels of NLRP3 inflam-
masome components were recently found to be significantly 
increased in peripheral blood mononuclear cells of BD patients 
with skin manifestations, compared to healthy controls, before 
and after lipopolysaccharide stimulation. Similarly, increased 
expression of the NLRP3 inflammasome was observed in BD 
skin lesions compared to tissues obtained from patients with 
erythema nodosum. Noteworthy, in the same study IL-1β secre-
tion in BD patients appeared to be related to NLRP3 inflamma-
some activation [13]. In this regard, another interesting study 
suggested IL-1β production by monocyte-derived macrophages 
through activation of the NLRP3 inflammasome by reactive 
oxygen species (ROS) resulting from mitochondria [14]. 
Interestingly, toll-like receptors (TLRs) 2, 4 and 9 were 
shown to be involved in the pathogenesis of BD [14,15]. These 
findings are intriguing, as TLRs represent a family of pattern 
recognition receptors involved in both innate and acquired 
immunity. In particular, TLR2 and TLR4, acting as signaling 
receptors activated by bacterial wall components, seem to 
up-regulate IL-1β production through a ROS-NLRP3 inflam-
masome pathway in active BD patients, implicating innate 
immunity mechanisms in BD pathogenesis [14,16]. In addi-
tion, genotype analysis revealed that some TLR-4 and TLR-9 
gene polymorphisms are significantly more frequent in BD 
patients than in healthy controls in Japanese and/or Turkish 
populations. Notably TLR-9, recognizing a component of bac-
terial DNA, was previously reported to be involved in other 
autoimmune/auto-inflammatory disorders, such as poly-
dermatomyositis and Crohn’s disease [15]. 
A further important clue to the auto-inflammatory hypoth-
esis is based on the expression of the P2X7 receptor (P2X7r) 
in monocytes from BD patients. The P2X7r is an ion channel 
triggered by adenosine triphosphate released by damaged cells. 
It plays a key role in promoting the release of pro-inflammatory 
cytokines, especially IL-1β, by inducing a massive potassium 
efflux that in turn accelerates the assembling of the NLRP3 
inflammasome, and then the maturation of pro-IL-1β. With 
regard to P2X7r, we found that BD patients display a higher 
monocyte surface expression and a higher sensitivity to stimu-
lation in terms of calcium permeability, when compared with 
healthy controls. In addition, monocytes from BD patients 
showed increased P2X7r-dependent IL-1β secretion. These 
results suggest a possible role of the innate immunity activation-
dependent inflammatory response in BD, supporting the view 
that IL-1 may be of pivotal pathogenic relevance [17]. 
Interestingly, some researchers recently suggested that 
decreased expression of C-type lectin domain family 12, mem-
ber A (CLEC12A), is a common denominator in the hyperin-
flammatory responses in both BD and gout, another established 
polygenic auto-inflammatory disorder. In particular, CLEC12A 
is a pattern-recognition receptor of innate immunity working as 
a negative regulator of inflammation by inhibiting granulocyte 
and monocyte/macrophage functions. Specifically, CLEC12A 
is capable of recognizing monosodium urate crystals, a well-
known stimulus for NLRP3-inflammasome. In this regard, 
beyond gout, BD is currently the only inflammatory condition 
exhibiting an increased response to monosodium urate crystal. 
However, further studies are needed to better establish the role 
of CLEC12A receptor in BD [18].
Table 1 summarizes current knowledge on the innate 
immune system in BD pathogenesis, distinguishing immune 
components in cells, cytokines, intracellular components, and 
surface receptors.
ClInICAl EVIDEnCE
The auto-inflammatory hypothesis was first proposed on the 
basis of clinical observations. In particular, many similari-
ties have been highlighted between BD and MAIS, including 
FMF, hyper-immunoglobulinemia D syndrome (HIDS), TNF 
receptor-associated periodic syndrome (TRAPS), CAPS, Blau 
syndrome, pyogenic arthritis, and pyoderma gangrenosum and 
acne (PAPA) syndrome. Specifically, bipolar aphthosis is often 
found in patients with HIDS, uveitis is also described in patients 
with Blau syndrome and severe CAPS, and BD skin manifesta-
tions are similar to those of PAPA syndrome. Furthermore, an 
association between acneiform skin lesions and arthritis has 
been documented in BD. Notably, the pathergy phenomenon 
has been described for both BD and PAPA syndrome [5].
A further clue suggesting a relationship between BD and 
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BD susceptibility genes are involved in the MAIS inflammatory 
pathways is still a matter of debate and research.
ThERAPEuTIC EVIDEnCE
The recently reported impressive clinical response to IL-1 inhi-
bition in BD patients is a further clue supporting the concept 
that IL-1 plays a pathological role in this disease [23-39]. To 
date, three anti-IL-1 agents have been tested in BD: the IL-1 
receptor antagonist anakinra, the anti-IL-1β monoclonal 
antibody canakinumab, and the recombinant humanized 
anti-IL-1β gevokizumab. Anakinra was first used by Botsios 
and colleagues [23] in 2008 as a monotherapy in a resistant 
BD patient, leading to a prompt and sustained response [23]. 
Two years later, anakinra proved beneficial in a teenage patient 
with FMF and BD complicated by secondary amyloidosis. 
In this case, treatment was effective in arresting clinical and 
laboratory inflammation, though proteinuria continued to 
deteriorate [24]. In the subsequent years an increasing number 
of case reports described the efficacy of anakinra in patients 
with protean BD clinical manifestations [25-28]. More recently, 
a survey on BD patients resistant to standard therapies showed 
that eight of nine patients responded to anakinra within 1–2 
weeks. However, most patients experienced a clinical relapse 
over time, and only one patient showed a complete response to 
anakinra treatment. However, responses to anakinra were on 
the whole effective, and anakinra was therefore continued in 
MAIS is the coexistence of BD and FMF in some patients 
[4,19]. Notably, a retrospective study of 4000 FMF patients 
found that 16 patients also met the International Study Group 
(ISG) diagnostic criteria for BD. The relatively high prevalence 
of BD among FMF patients suggests that FMF and BD occur 
together more commonly than expected [4]. In addition, the 
hypothesis that FMF may be induced in subjects with a FMF-
related mutation and coexistent inflammatory conditions, such 
as BD, was also proposed [19]. These exciting observations 
seem to be corroborated by epidemiologic data showing an 
overlapping geographic distribution for both clinical entities 
[1-3]. Interestingly, frequencies of FMF-related mutations in 
BD patients were found in up to 40.4% of cases, and positivity 
of single mutations seems to be more frequent in BD patients 
with vascular involvement and thrombosis. However, other 
authors did not find consistent results and suggested that BD 
and FMF merely represent two separate entities with no mutual 
effect and a mild trend toward a higher than expected associa-
tion. Thus, the question remains unresolved [20]. 
Regarding TRAPS, the low penetrance mutation R92Q has 
been associated with an increased risk of extracranial venous 
thrombosis in patients diagnosed with BD [21]. Similarly, 
mutations responsible for HIDS have been described in patients 
with typical BD features, but no significant increase of HIDS, 
CAPS or PAPA syndrome-related mutations was found in 
patients with BD when compared with controls [22]. Whether 
Table 1. Current pathogenetic evidence on the innate immune system involvement in Behçet’s disease
Innate immunity 
components Players Involvement in BD
Cells Neutrophils Activation by a subset of IL-8-producing T cells [8]
Macrophages Production of IL-1β through activation of the NLRP3 inflammasome by ROS [14]
Monocytes Increased P2X7r-dependent IL-1β secretion in BD [17]
Cytokines IL-1 Significantly higher in patients with both active and inactive BD compared to healthy controls [9]
Polymorphism of IL-1 gene significantly more represented in patients with BD [11]
IL-33 Increased in serum from BD patients along with its soluble ligand sST2 [10]
Soluble ligand correlates with BD activity [10]
Highly expressed in the epidermis and dermis of patients with BD [10]
Intracellular 
proteins
NLRP3 inflammasome NLRP3 components significantly increased in peripheral blood mononuclear cells from BD patients and in BD skin 
lesions, compared to healthy controls and erythema nodosum patients, respectively [13]
IL-1β secretion in BD related to NLRP3 inflammasome activation [13,14]
IL-1β production by monocyte-derived macrophages via NLRP3 inflammasome induced by ROS [14]
Surface receptors TLR TLR-2 and -4 upregulate IL-1β production through a ROS-NLRP3 inflammasome pathway [14,16]
TLR-4 and TLR-9 gene polymorphisms significantly more frequent in BD patients than healthy controls [15]
P2X7r Higher monocyte surface expression in BD than healthy controls [17]
Higher sensitivity to stimulation when compared to healthy controls [17]
Increased P2X7r-dependent IL-1β secretion in BD [17]
BD = Behçet’s disease, IL = interleukin, P2X7r = P2X7 receptor, ROS = reactive oxygen species, TLR = Toll-like receptors, NLRP3 = NACHT, LRR, and PYD 
domains-containing protein 3
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drug survival was acceptable for both IL-1 inhibitors evaluated 
and no serious adverse events were reported [36]. The excellent 
safety profile of anti-IL1 agents in BD has been confirmed by 
another recent multicenter observational cohort study specifi-
cally evaluating biologic agents [37]. 
A third anti-IL-1 agent, gevokizumab, has also been assessed 
in BD patients with refractory multiresistant and sight-threat-
ening uveitis: a single intravenous infusion of gevokizumab 
(dosage 0.3 mg/kg) led to rapid and complete resolution of 
intraocular inflammation with marked improvement of visual 
acuity in 21 days. Moreover, five patients re-treated with 
gevokizumab for recurrent uveitis responded to a second dose, 
maintaining their response for several months and despite any 
discontinuation of immunosuppressive agents or increase in 
the corticosteroid dosage [38].
Notably, the importance of IL-1 inhibition in BD patients 
also derives from an epidemiologic observation: unlike anti-
TNFα agents, IL-1 antagonists do not seem to interfere signifi-
cantly with the risk of tuberculosis, suggesting that anti-IL-1 
agents are a feasible treatment in areas where tuberculosis is 
endemic [39]. 
Tables 2 and 3 summarize published clinical studies on the 
efficacy of IL-1 inhibitors in patients diagnosed with BD. 
COnCluSIOnS
An increasing volume of evidence places BD at the crossroad 
between autoimmune and auto-inflammatory disorders. In 
the present review we have considered pathogenetic, clinical 
and therapeutic elements supporting the auto-inflammatory 
most patients for a mean period of 13 months. Notably, increas-
ing the dose of anakinra led to good clinical responses when 
the effective standard dose was unsuccessful. Conversely, a less 
remarkable response was observed for mucocutaneous mani-
festations [29]. Nonetheless, anakinra ineffectiveness was also 
described in BD patients [29-31]. For such patients the anti-
IL-1β agent canakinumab can be a useful therapeutic choice 
[29,32-37]. In 2012 two case reports described canakinumab 
as an effective treatment in counteracting BD stigmata and 
normalizing all markers of inflammation at a dosage of 150 
mg every 8 weeks [32,33]. In 2014, we reported three addi-
tional patients with complete remission during a 6–12 month 
follow-up. However, canakinumab led to better results when 
administered every 6 weeks [34]. Moreover, canakinumab at a 
dose of 4 mg/kg every 28 days was proven useful and safe also 
when administered in children with BD [35]. 
More recently, we performed a multicenter retrospective 
study aimed at evaluating the efficacy of both anakinra and 
canakinumab in a cohort of 30 BD patients. In accordance with 
previously reported data, our results showed that BD patients 
with an initial low response to anakinra recovered completely 
following an increase in the drug dose. Alternatively, switch-
ing to canakinumab after anakinra failure represented another 
therapeutic opportunity for refractory patients. Furthermore, 
patients experiencing a disease relapse while on canakinumab 
administered at 150 mg every 8 weeks could benefit by short-
ening the interval between administrations to 150 mg every 6 
weeks. The median time of response to therapy was 6 weeks 
for anakinra and 3 weeks for canakinumab. In addition, the 
Table 2. Overview of studies reporting patients with Behçet’s disease treated with anakinra 
Autors [ref]
no. of 
patients Main clinical involvement Dosage Results
Botsios et al. [23] 1 Mucocutaneous, gastrointestinal, fever 100 mg/day Complete remission in 7–10 days
Bilginer et al. [24] 1 Mucocutaneous, articular, fever, amyloidosis 1 mg/kg/day Complete remission during 18 months follow-up; amyloidosis-related 
proteinuria increased
Emmi et al. [25] 1 Mucocutaneous, ocular, gastrointestinal, articular 100 mg/day Complete remission during 12 months follow-up
Caso et al. [26] 1 Mucocutaneous, ocular, articular 100 mg/day Complete remission in a few days
Emmi et al. [28] 2 Mucocutaneous, gastrointestinal, articular (1/2) 100 mg/day First patient: complete remission during 8 months follow-up;
second patient: data not yet available
Cantarini et al. [29] 9 Ocular (5/9), cutaneous (4/9), articular (6/9), fever 
(5/9)
Up to 150 mg/day 
(adults), up to 2.5 
mg/kg/day (children)
Eight of 9 patients showed prompt improvement after starting anakinra;  
7 patients had a relapse in a mean period of 29 weeks
Caso et al. [30] 1 Mucocutaneous, musculoskeletal, ocular; the 
patient complained also of pemphigus
100 mg/day Partial improvement lasting for only 20 days
Vitale et al. [31] 1 Mucocutaneous, ocular, articular, neurological, 
fever
100 mg/day Complete remission during 18 months follow-up; ocular relapse after 18 
months 
Pagnini et al. [35] 1 Mucocutaneous, ocular, fever 4 mg/kg/day Partial response; a switch to canakinumab was needed after 19 months 
of therapy
Emmi et al. [36] 27 Mucocutaneous, ocular, neurological, 
gastroenteric, vascular, articular
100 mg/day The median time of response to anakinra was 6 weeks; adherence to 
treatment in 75th percentile of 2.0 months and median 6.0 months, with 
overall cumulative treatment survival of 26.3% at 24 months. No adverse 
events recorded. Six patients shifted from anakinra to canakinumab
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cologic therapy in Kawasaki syndrome and management of its cardiovascular 
complications. Eur Rev Med Pharmacol Sci 2007; 11: 301-8.
7. Caso F, Costa L, Rigante D, et al. Biological treatments in Behçet’s disease: beyond 
anti-TNF therapy. Mediators Inflamm 2014; 2014: 107421.
8. Keller M, Spanou Z, Schaerli P, et al. T cell-regulated neutrophilic inflammation in 
autoinflammatory diseases. J Immunol 2005; 175: 7678-86.
9. Mege JL, Dilsen N, Sanguedolce V, et al. Overproduction of monocyte derived 
tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil 
superoxide generation in Behçet’s disease. A comparative study with familial 
Mediterranean fever and healthy subjects. J Rheumatol 1993; 20: 1544-9.
10. Kim DJ, Baek SY, Park MK, et al. Serum level of interleukin-33 and soluble ST2 and 
their association with disease activity in patients with Behcet’s disease. J Korean 
Med Sci 2013; 28: 1145-53.
11. Liang Y, Xu WD, Zhang M, et al. Meta-analysis of association between cytokine 
gene polymorphisms and Behcet’s disease risk. Int J Rheum Dis 2013; 16: 616-24. 
12. Rigante D, Vitale A, Lucherini OM, Cantarini L. The hereditary autoinflammatory 
disorders uncovered. Autoimmun Rev 2014; 13: 892-900. 
13. Kim EH, Park MJ, Park S, Lee ES. Increased expression of the NLRP3 infla- 
mmasome components in patients with Behçet’s disease. J Inflamm (Lond) 2015; 
12: 41.
14. Liang L, Tan X, Zhou Q, et al. IL-1β triggered by peptidoglycan and lipo- 
polysaccharide through TLR2/4 and ROS-NLRP3 inflammasome-dependent 
pathways is involved in ocular Behçet’s disease. Invest Ophthalmol Vis Sci 2013; 54: 
402-14.
15. Sakamoto N, Sekine H, Kobayashi H, Sato Y, Ohira H. Association of the toll-like 
receptor 9 gene polymorphisms with Behcet’s disease in a Japanese population. 
Fukushima J Med Sci 2012; 58: 127-35.
16. Kirino Y, Zhou Q, Ishigatsubo Y, et al. Targeted resequencing implicates the 
familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 
in Behçet disease. Proc Natl Acad Sci USA 2013; 110: 8134-9.
17. Castrichini M, Lazzerini PE, Gamberucci A, et al. The purinergic P2×7 receptor 
is expressed on monocytes in Behçet’s disease and is modulated by TNF-α. Eur J 
Immunol 2014; 44: 227-38.
18. Oğuz AK, Yılmaz S, Akar N, et al. C-type lectin domain family 12, member A: 
a common denominator in Behçet’s syndrome and acute gouty arthritis. Med 
Hypotheses 2015; 85:186-91.
19. Livneh A, Aksentijevich I, Langevitz P, et al. A single mutated MEFV allele in 
Israeli patients suffering from familial Mediterranean fever and Behçet’s disease 
(FMF-BD). Eur J Hum Genet 2001; 9: 191-6.
20. Aksu K, Keser G. Coexistence of vasculitides with familial Mediterranean fever. 
Rheumatol Int 2011; 31: 1263-74.
21. Amoura Z, Dodé C, Hue S, et al. Association of the R92Q TNFRSF1A mutation 
hypothesis. However, other clues highlight the autoimmune 
component at the basis of BD, such as class I major histocom-
patibility complex associations and response to treatment with 
immunosuppressive agents. In addition, the therapeutic benefit 
observed with interferon-α supports the hypothesis of a Th1-
driven disease [40]. On the whole, these observations confirm 
the complexity of BD due to the extremely protean clinical 
picture and the difficult management. Of note, anti-IL-1 agents 
are proving to be a valid treatment tool in patients resistant to 
standard therapies; by bolstering TNF inhibition, they could be 
the treatment of choice when anti-TNF agents are not advisable. 
In this context, looking far into the future, investigating predic-
tive factors of response to therapy and identifying the optimal 
dosages or intervals of administration are interesting challenges. 
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Chronic pulmonary silicone embolism related to saline 
breast implants has been detailed in a letter to the editor 
published in the January issue of the Annals of the American 
Thoracic Society. Ayush Arora, from the Cleveland Clinic, 
and colleagues describe the first case of pulmonary silicone 
embolism related to saline breast implants in a 45 year old 
woman. The patient had been repeatedly hospitalized over 
the course of 14 months with a clinical presentation that 
included acute dyspnea on exertion and fever, and bilateral 
lung infiltrates on chest radiograph. The patient had undergone 
bilateral breast augmentation with saline implants 18 years 
earlier. The researchers note that on examination the implants 
were found to be in place, although there was marked asym- 
metry, the right implant being considerably smaller. There 
was slight but notable distortion of the right implant, with 
a potion seemingly embedded in the chest wall. Review of 
pathology slides showed the presence of multiple clear 
vacuoles surrounded by histiocytes and/or multinucleated giant 
cells. The morphology was consistent with silicone emboli. The 
patient was diagnosed with chronic pulmonary silicone emboli 
and referred for implant removal. The authors conclude: “In 
summary, silicone microemboli derived from breast implants 
can potentially embolize to the lung, causing a chronic form of 
lung disease mimicking interstitial lung disease.” 
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Breast implants linked to chronic pulmonary silicone embolism
The transcription factor GATA-3 is indispensable for the 
development of all innate lymphoid cells (ILCs) that express 
the interleukin 7 receptor α-chain (IL-7Rα). However, the 
function of low GATA-3 expression in committed group 
3 ILCs (ILC3 cells) has not been identified. Zhong et al. 
found that GATA-3 regulated the homeostasis of ILC3 cells 
by controlling IL-7Rα expression. In addition, GATA-3 served 
a critical function in the development of the NKp46+ ILC3 
subset by regulating the balance between the transcription 
factors T-bet and RORγt. Among NKp46+ ILC3 cells, although 
GATA-3 positively regulated genes specific to the NKp46+ ILC3 
subset, it negatively regulated genes specific to lymphoid 
tissue inducer (LTi) or LTi-like ILC3 cells. Furthermore, GATA-
3 was required for IL-22 production in both ILC3 subsets. 
Thus, despite its low expression, GATA-3 was critical for the 
homeostasis, development and function of ILC3 subsets. 
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Group 3 innate lymphoid cells continuously require the transcription factor GATA-3 after commitment
